In his tenth year as NIH Director, Francis Collins is expanding the reach of marquee programs launched under his tenure, and growing the institutes’ footprint in artificial intelligence.
In a conversation with BioCentury, Collins identified his top priorities for the new year, and discussed emerging scientific areas that stand to make a big impact on drug development.
He called out single cell analysis, CRISPR and AI as technologies poised to deliver a wealth of new translational insights, and said NIH plans to invest in data collection and workforce development to support AI.
